Why did Crestchem's profit not grow despite higher revenue?

The filing doesn't break down costs, but flat profit on 18% revenue growth implies margin compression. Rising input or operating costs likely offset the top-line gain.

What is the dividend recommended by the board?

The board recommended a final dividend of ₹1.50 per share for FY26, subject to shareholder approval.

Is the ₹2.25 crore investment in Oleo Biosciences new news?

No. The investment was previously disclosed as a proposed agenda item. This board meeting merely gave formal approval.

How has Crestchem performed historically?

In FY26, revenue rose 18% to ₹29.61 crore from ₹25.07 crore, but net profit slipped marginally to ₹2.71 crore from ₹2.73 crore. The company has zero debt and a trailing ROE of 36.5%.

Earnings · Chemicals · Micro cap

Crestchem revenue up 18% but profit flat at ₹2.71 cr

Revenue grew to ₹29.61 crore in FY26, but net profit stayed virtually unchanged at ₹2.71 crore. Board recommends ₹1.50 dividend per share.

— 1 earlier story on Crestchem Ltd. →

CRSTCHM By Tipsheet Editorial 19 Jun 2026 · 6:36 PM IST Verify on BSE · NSE

Mkt cap₹39.13 cr

P/E14.43×

ROE36.47%

Debt / eq.0.00

₹2.71 cr FY26 net profit, flat YoY

What's new

Revenue grew 18% to ₹29.61 cr, but net profit flat at ₹2.71 cr vs ₹2.73 cr last year.
Board recommends final dividend of ₹1.50 per share for the year.
Formally approved ₹2.25 cr investment in subsidiary Oleo Biosciences, previously disclosed.

Why this matters

For a debt-free nano-cap with 36.5% ROE, a stagnant profit on higher revenue suggests margin compression. The dividend offers a modest return, while the biosciences investment is a small but strategic bet.

What we're watching

Whether margin pressure eases in H1 FY27 or continues.
Progress at Oleo Biosciences and its impact on future growth.
Scope for higher dividends given strong cash generation.

The full read

Crestchem's FY26 numbers show a familiar pattern: revenue up 18% to ₹29.61 crore, but profit stuck at ₹2.71 crore — almost identical to last year's ₹2.73 crore. That's margin compression in plain sight. For a debt-free nano-cap with 36.5% ROE, every rupee of extra revenue getting eaten by costs is the one number to track. The ₹2.25 crore investment in Oleo Biosciences and the ₹1.50 dividend were already baked in. The margin squeeze makes FY27 the test of whether Crestchem can turn top-line growth into bottom-line gains.

Questions answered

Why did Crestchem's profit not grow despite higher revenue?: The filing doesn't break down costs, but flat profit on 18% revenue growth implies margin compression. Rising input or operating costs likely offset the top-line gain.
What is the dividend recommended by the board?: The board recommended a final dividend of ₹1.50 per share for FY26, subject to shareholder approval.
Is the ₹2.25 crore investment in Oleo Biosciences new news?: No. The investment was previously disclosed as a proposed agenda item. This board meeting merely gave formal approval.
How has Crestchem performed historically?: In FY26, revenue rose 18% to ₹29.61 crore from ₹25.07 crore, but net profit slipped marginally to ₹2.71 crore from ₹2.73 crore. The company has zero debt and a trailing ROE of 36.5%.

Mentioned: ₹29.61 cr revenue · ₹2.71 cr profit · Oleo Biosciences

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Crestchem Ltd.

Chemicals

₹39 cr

P/E 14.45×

Latest quarter · Mar 2026

Sales₹10 cr

Net profit₹1 cr

Op. margin+13.7%

EPS₹3.68

Strength & growth

Debt / equity0.00×

Current ratio1.44×

Sales CAGR+82.6%

EPS CAGR+50.8%

Story so far

All notes on CRSTCHM →

19 Jun 2026 · 6:36 PM IST Crestchem revenue up 18% but profit flat at ₹2.71 cr
17d ago Crestchem's FY26 revenue rises 18% but profit flat